title: Evaluations of activated clotting time technologies require understanding activating clotting time system differences.
authors.forename: Marcia L
authors.initials: ML
authors.lastname: Zucker
mesh_terms: D001777:Blood Coagulation / Q000187:drug effects* / Q000502:physiology*; D016903:Drug Monitoring / Q000295:instrumentation*; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D019095:Point-of-Care Systems; D014914:Whole Blood Coagulation Time / Q000295:instrumentation*
chemical_list: D006493:Heparin